SERUM PLACENTAL-TYPE ALKALINE-PHOSPHATASE LEVELS IN PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA
- TEJ IND
- RK ILES
- K DESOUZA
- P CARTER
- D LOWE
- JH SHEPHERD
- CN HUDSON
- T CHARD
Affiliations: UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT REPROD PHYSIOL,LONDON EC1A 7BE,ENGLAND. UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT GYNAECOL ONCOL,LONDON EC1A 7BE,ENGLAND. UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT PATHOL,LONDON EC1A 7BE,ENGLAND.
- Published online on: February 1, 1995 https://doi.org/10.3892/ijo.6.2.385
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Serum placental alkaline phosphatase (PLAP)-type immunoreactivity was measured in 190 women with epithelial ovarian malignancy, 27 women with borderline ovarian cancer and 334 control subjects with non-neoplastic or benign gynaecological disease. Smoking, ABO blood group and menopausal status affect serum concentrations of PLAP and results were corrected for these. Circulating levels were elevated in patients with cancer and increased with stage. Levels were unaltered in borderline ovarian disease. Two-year stage corrected survival analysis demonstrated a significant worsening of prognosis in patients with serum PLAP-type levels greater than the 100th centile for controls.